Liquidia Corporation
Every calculator, already run for LQDA
Open the full toolkit →You have the numbers on LQDA. Get the argument.
A written report on which of these readings actually decide the outcome for Liquidia Corporation, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
8 analysts covering LQDAAnalyst Price Target Disagreement for Liquidia Corporation
Wall Street's bull case implies +53% from the current price; the bear case implies -28%. A 81% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for LQDA
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension…
LQDA — frequently asked
Is LQDA a buy right now?
Wall Street's consensus rating on Liquidia Corporation is Buy across 8 analysts, with a mean price target of $54.38 (+19% vs. the current $45.82). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is LQDA overvalued?
LQDA trades at 33.0x trailing earnings, against a DCF fair value of $24 per share. The current price implies 14% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is LQDA's next earnings date?
Liquidia Corporation is next scheduled to report earnings around Nov 3, 2026. A full LQDA research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Liquidia Corporation?
Analysts covering Liquidia Corporation (LQDA) range from a bear-case target of $33.00 to a bull-case high of $70.00, with a mean consensus target of $54.38 across 8 analysts. The spread of $37.00 (81% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Liquidia Corporation against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Liquidia Corporation
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full LQDA research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Liquidia Corporation, in minutes. 3 free reports included with every account — no credit card required.